JP2024514344A5 - - Google Patents
Info
- Publication number
- JP2024514344A5 JP2024514344A5 JP2023564087A JP2023564087A JP2024514344A5 JP 2024514344 A5 JP2024514344 A5 JP 2024514344A5 JP 2023564087 A JP2023564087 A JP 2023564087A JP 2023564087 A JP2023564087 A JP 2023564087A JP 2024514344 A5 JP2024514344 A5 JP 2024514344A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- seq
- amino acid
- stable aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177518P | 2021-04-21 | 2021-04-21 | |
| US63/177,518 | 2021-04-21 | ||
| US202163180690P | 2021-04-28 | 2021-04-28 | |
| US63/180,690 | 2021-04-28 | ||
| US202263309230P | 2022-02-11 | 2022-02-11 | |
| US63/309,230 | 2022-02-11 | ||
| PCT/IB2022/053733 WO2022224187A1 (en) | 2021-04-21 | 2022-04-21 | High concentration bispecific antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514344A JP2024514344A (ja) | 2024-04-01 |
| JP2024514344A5 true JP2024514344A5 (https=) | 2026-01-06 |
Family
ID=81579656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564087A Pending JP2024514344A (ja) | 2021-04-21 | 2022-04-21 | 高濃度二重特異性抗体製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220395573A1 (https=) |
| EP (1) | EP4326242A1 (https=) |
| JP (1) | JP2024514344A (https=) |
| KR (1) | KR20230174239A (https=) |
| AU (1) | AU2022260814A1 (https=) |
| BR (1) | BR112023021549A2 (https=) |
| CA (1) | CA3217191A1 (https=) |
| CR (1) | CR20230497A (https=) |
| EC (1) | ECSP23080283A (https=) |
| IL (1) | IL307879A (https=) |
| JO (1) | JOP20230263A1 (https=) |
| MX (1) | MX2023012508A (https=) |
| PE (1) | PE20240805A1 (https=) |
| PH (1) | PH12023552883A1 (https=) |
| TW (1) | TW202308689A (https=) |
| UY (1) | UY39734A (https=) |
| WO (1) | WO2022224187A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI907491B (zh) * | 2020-08-26 | 2025-12-11 | 美商健生生物科技公司 | 包括雙特異性egfr/c-met抗體之穩定調配物 |
| WO2024003837A1 (en) | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| AU2024337472A1 (en) | 2023-09-05 | 2026-04-16 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| CN119700964A (zh) * | 2023-09-28 | 2025-03-28 | 上海翰森生物医药科技有限公司 | 一种双特异性抗体在制备治疗癌症的药物中的用途 |
| WO2025079020A1 (en) | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer |
| WO2025158277A1 (en) | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
| WO2025191459A1 (en) | 2024-03-11 | 2025-09-18 | Janssen Biotech, Inc. | Use of bispecific anti-egfr/c-met antibodies to treat solid tumors |
| WO2025227052A1 (en) * | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
| WO2026022733A1 (en) | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
| WO2026022739A1 (en) | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| CA2450285C (en) * | 2001-06-13 | 2016-08-02 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| TWI395593B (zh) * | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| HRP20241208T1 (hr) * | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| TWI907491B (zh) * | 2020-08-26 | 2025-12-11 | 美商健生生物科技公司 | 包括雙特異性egfr/c-met抗體之穩定調配物 |
| EP4210702A1 (en) * | 2020-09-14 | 2023-07-19 | JANSSEN Pharmaceutica NV | Fgfr inhibitor combination therapies |
-
2022
- 2022-04-20 TW TW111114958A patent/TW202308689A/zh unknown
- 2022-04-21 JP JP2023564087A patent/JP2024514344A/ja active Pending
- 2022-04-21 EP EP22720780.0A patent/EP4326242A1/en active Pending
- 2022-04-21 US US17/725,755 patent/US20220395573A1/en not_active Abandoned
- 2022-04-21 CA CA3217191A patent/CA3217191A1/en active Pending
- 2022-04-21 AU AU2022260814A patent/AU2022260814A1/en active Pending
- 2022-04-21 PH PH1/2023/552883A patent/PH12023552883A1/en unknown
- 2022-04-21 CR CR20230497A patent/CR20230497A/es unknown
- 2022-04-21 BR BR112023021549A patent/BR112023021549A2/pt unknown
- 2022-04-21 KR KR1020237039536A patent/KR20230174239A/ko active Pending
- 2022-04-21 WO PCT/IB2022/053733 patent/WO2022224187A1/en not_active Ceased
- 2022-04-21 UY UY0001039734A patent/UY39734A/es unknown
- 2022-04-21 MX MX2023012508A patent/MX2023012508A/es unknown
- 2022-04-21 IL IL307879A patent/IL307879A/en unknown
- 2022-04-21 PE PE2023002909A patent/PE20240805A1/es unknown
-
2023
- 2023-10-19 JO JOJO/P/2023/0263A patent/JOP20230263A1/ar unknown
- 2023-10-20 EC ECSENADI202380283A patent/ECSP23080283A/es unknown
-
2025
- 2025-03-06 US US19/072,332 patent/US20250195649A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514344A5 (https=) | ||
| JP6779997B2 (ja) | Ｐｄ１／ｃｔｌａ４結合性物質 | |
| JP2024102215A5 (https=) | ||
| RU2762746C2 (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2022532927A5 (https=) | ||
| JP2023540025A5 (https=) | ||
| JP2024544523A5 (https=) | ||
| RU2008141433A (ru) | Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| JP2016530323A5 (https=) | ||
| RU2007118648A (ru) | Композиции антител | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| RU2017123972A (ru) | Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF) | |
| US20240067720A1 (en) | Anti-tigit antibody pharmaceutical composition and application thereof | |
| US20140079665A1 (en) | Therapeutic anti-igf1r combinations | |
| JP2025500784A5 (https=) | ||
| JP2023504748A5 (https=) | ||
| JP2023539589A5 (https=) | ||
| JP2024515968A5 (https=) | ||
| CN110732023A (zh) | 一种her2抗体药物组合物及其用途 | |
| TW201907951A (zh) | 用於男性及女性型態掉髮之催乳素受體抗體 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2023507795A5 (https=) |